MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 https://www.businesswire.com/news/h...-with-Three-Phase-3-Readouts-Expected-in-2026
GO TO THIS URL: https://ir.definiumtx.com/news-even...-44th-annual-j-p-morgan-healthcare-conference Click the Webcast Link at 5:15pm EST
Definium defines mental health applications for LSD in new awareness campaign https://www.fiercepharma.com/market...zempic-push-starring-justin-long-john-hodgman
PATENT GRANTED - $DFTX Immediate release formulations of d-lysergic acid diethylamide for therapeutic applications https://ppubs.uspto.gov/api/patents...4LTRlZWQtYTBiOC0yYjdjZjJhZWMwNDAiLCJleHAiOjB9
Reminder All Older Posts prior to company name change can be found here: https://stockaholics.net/threads/mnmd-mindmed-inc.12024/
Definium Therapeutics stock price target raised to $36 from $20 at RBC Capital $DFTX www.investing.com/news/analyst-ratings/definium-therapeutics-stock-price-target-raised-to-36-from-20-at-rbc-capital-93CH-4462617
NJ Psilocybin Legislation Exposes Conflicts Between Advocates for Different Therapeutic Models https://www.lucid.news/nj-psilocybin-legislation-exposes-conflicts-between-advocates-for-different-therapeutic-models/ There’s a lot of tension in the article around “pharma gatekeeping” vs grassroots access to natural mushrooms. But if you strip away the politics and look at what actually came out of this, it reinforces something we’ve seen over and over. When states get serious, they default to hospital-based, physician-led, FDA-aligned models. Bullish for the synthetic companies
